Compare ANET & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANET | TMO |
|---|---|---|
| Founded | 2004 | 1956 |
| Country | United States | United States |
| Employees | 4412 | N/A |
| Industry | Computer Communications Equipment | Industrial Machinery/Components |
| Sector | Telecommunications | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.1B | 216.4B |
| IPO Year | 2014 | N/A |
| Metric | ANET | TMO |
|---|---|---|
| Price | $132.40 | $566.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $163.00 | ★ $631.00 |
| AVG Volume (30 Days) | ★ 7.3M | 1.7M |
| Earning Date | 11-04-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | ★ 26.15 | 8.54 |
| EPS | 2.63 | ★ 17.32 |
| Revenue | $8,448,346,000.00 | ★ $43,736,000,000.00 |
| Revenue This Year | $29.41 | $4.33 |
| Revenue Next Year | $21.54 | $4.94 |
| P/E Ratio | $49.86 | ★ $32.79 |
| Revenue Growth | ★ 27.75 | 3.22 |
| 52 Week Low | $59.43 | $385.46 |
| 52 Week High | $164.94 | $610.97 |
| Indicator | ANET | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 45.83 |
| Support Level | $121.63 | $554.53 |
| Resistance Level | $127.84 | $579.08 |
| Average True Range (ATR) | 5.00 | 11.13 |
| MACD | 0.64 | -2.68 |
| Stochastic Oscillator | 71.80 | 31.48 |
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).